Crinetics Pharmaceuticals, Inc. (CRNX) financial statements (2020 and earlier)

Company profile

Business Address 10222 BARNES CANYON ROAD, BLDG. #2
SAN DIEGO, CA 92121
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:118164
Cash and cash equivalents4045
Short-term investments78119
Other undisclosed cash, cash equivalents, and short-term investments00
Receivables01
Other current assets11
Other undisclosed current assets31
Total current assets:123167
Noncurrent Assets
Operating lease, right-of-use asset3
Property, plant and equipment44
Restricted cash and investments11
Other noncurrent assets0 
Total noncurrent assets:75
TOTAL ASSETS:130171
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:58
Accounts payable 1
Accrued liabilities 4
Employee-related liabilities 2
Other undisclosed accounts payable and accrued liabilities5 
Debt1 
Other liabilities1 
Other undisclosed current liabilities1 
Total current liabilities:88
Noncurrent Liabilities
Long-term debt and lease obligation5 
Operating lease, liability5
Liabilities, other than long-term debt03
Deferred compensation liability, classified00
Deferred rent credit 3
Total noncurrent liabilities:53
Total liabilities:1311
Stockholders' equity
Stockholders' equity attributable to parent, including:117160
Common stock 0
Additional paid in capital 204
Accumulated other comprehensive income00
Accumulated deficit(94)(43)
Other undisclosed stockholders' equity attributable to parent211 
Total stockholders' equity:117160
TOTAL LIABILITIES AND EQUITY:130171

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
Gross profit:12
Operating expenses(55)(31)
Operating loss:(54)(29)
Nonoperating income32
Investment income, nonoperating32
Net loss available to common stockholders, diluted:(50)(27)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
Net loss:(50)(27)
Other comprehensive income00
Comprehensive loss, net of tax, attributable to parent:(50)(27)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: